Literature DB >> 7494231

Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma.

R A Kratzke1, G A Otterson, C E Lincoln, S Ewing, H Oie, J Geradts, F J Kaye.   

Abstract

BACKGROUND: The identification in 1994 of the CDKN2 gene as a target for mutations in a wide range of human cancers, including malignant mesothelioma, has been controversial because subsequent studies have detected a lower frequency of CDKN2 gene mutations in primary tumors than in cultured cell lines. These reports raised the hypothesis that another gene, distinct from CDKN2, might be the target of the chromosome 9p21 deletions frequently observed in these tumors.
PURPOSE: To address whether inactivation of CDKN2 function is an essential event in the etiology of malignant mesothelioma, we examined p16INK4 protein expression in primary thoracic mesotheliomas, in nonmalignant pleural tissues, and in independent mesothelioma cell lines. We also studied the growth rate of tumor cell lines following stable transfection of CDKN2 gene.
METHODS: Retinoblastoma (Rb) and p16INK4 protein expression was determined by immunohistochemical analysis from archival paraffin specimens of 12 primary thoracic mesotheliomas and a nonmalignant pleural biopsy specimen. In addition, protein immunoblot analysis for Rb and p16INK4 expression was conducted on 15 independent mesothelioma cell lines, and the ability of a transfected CDKN2 gene to suppress the growth of the mesothelioma cell lines H2373 and H2461 in vitro was examined.
RESULTS: We demonstrated abnormal p16INK4 expression in 12 of 12 primary mesothelioma specimens and in 15 of 15 mesothelioma cell lines. All tumor specimens and the tumor cell lines showed expression of wild-type Rb protein. In addition, we have confirmed the ability of a transfected CDKN2 gene to suppress growth of two independent mesothelioma cell lines.
CONCLUSIONS: Immunohistochemical analysis of the p16INK4 gene product is feasible in archival biopsy samples. With this analysis, CDKN2 gene inactivation can be determined in tumors that are contaminated with nonmalignant cells. Furthermore, since loss of p16INK4 protein expression can result from both genetic (gene mutations) and epigenetic (abnormal DNA hypermethylation) mechanisms, as we and others have shown recently, examination of protein expression is a highly sensitive method for analyzing the CDKN2 status in large numbers of tumor samples. IMPLICATIONS: This study suggests that inactivation of the CDKN2 gene is an essential step in the etiology of malignant mesotheliomas. Defining the role of the p16INK4:Rb tumor suppressor pathway and its immediate downstream substrates will be an important goal in designing future therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494231     DOI: 10.1093/jnci/87.24.1870

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  20 in total

1.  Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.

Authors:  Michele Carbone; Haining Yang
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

2.  Molecular biology of malignant mesothelioma.

Authors:  Yoshitaka Sekido
Journal:  Environ Health Prev Med       Date:  2008-02-28       Impact factor: 3.674

3.  Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression.

Authors:  R Villuendas; M Sánchez-Beato; J C Martínez; A I Saez; B Martinez-Delgado; J F García; M S Mateo; L Sanchez-Verde; J Benítez; P Martínez; M A Piris
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

Review 4.  Molecular diagnosis of pancreas carcinoma.

Authors:  T M Chu
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

5.  Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.

Authors:  Geula Klorin; Ester Rozenblum; Oleg Glebov; Robert L Walker; Yoonsoo Park; Paul S Meltzer; Ilan R Kirsch; Frederic J Kaye; Anna V Roschke
Journal:  Cancer Genet       Date:  2013-07-05

6.  Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis.

Authors:  Solange Romagnoli; Ester Fasoli; Valentina Vaira; Monica Falleni; Caterina Pellegrini; Anna Catania; Massimo Roncalli; Antonio Marchetti; Luigi Santambrogio; Guido Coggi; Silvano Bosari
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

7.  Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma.

Authors:  Ryota Hama; Yoshiyuki Watanabe; Kanako Shinada; Yosuke Yamada; Yuka Ogata; Yoshihito Yoshida; Tomohiro Tamura; Tetsuya Hiraishi; Ritsuko Oikawa; Jo Sakurai; Tadateru Maehata; Hirotaka Koizumi; Fumio Itoh
Journal:  Tumour Biol       Date:  2012-07-27

8.  Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice.

Authors:  Deborah A Altomare; Craig W Menges; Jianming Pei; Lili Zhang; Kristine L Skele-Stump; Michele Carbone; Agnes B Kane; Joseph R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-17       Impact factor: 11.205

Review 9.  Peritoneal mesothelioma.

Authors:  R N Taub; M L Keohan; J C Chabot; K S Fountain; M Plitsas
Journal:  Curr Treat Options Oncol       Date:  2000-10

10.  Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma.

Authors:  B A Jacobson; A De; M G Kratzke; M R Patel; J Jay-Dixon; B A Whitson; A A Sadiq; P B Bitterman; V A Polunovsky; R A Kratzke
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.